Skip to main content

Animations

MJFF Publications

441 - 450 of 6516 Results
Title
Year
  • Year
  • 2023
  • 2022
  • 2021
  • 2021
  • 2020
  • 2021
  • 2021
  • 2021
  • 2021
  • 2021
  • Summary Details
    OPEN
    Title: Patients’ Preferences for Adjunctive Parkinson’s Disease Treatments: A Discrete-Choice Experiment
    Journal Name: Patient Preference and Adherence
    Publisher: Informa UK Limited
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.2147/ppa.s420051
    Citation Count: 4
  • Summary Details
    OPEN
    Title: Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs
    Journal Name: ACS Chemical Neuroscience
    Publisher: American Chemical Society (ACS)
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1021/acschemneuro.2c00597
    Citation Count: 65
  • Summary Details
    OPEN
    Title: Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression: An exploratory study in the PPMI database
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.03.007
    Citation Count: 21
  • Summary Details
    OPEN
    Title: Falling down the digital divide: A cautionary tale
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.10.032
    Citation Count: 5
  • Summary Details
    OPEN
    Title: Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®)
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.12.002
    Citation Count: 7
  • Plasma NfL, clinical subtypes and motor progression in Parkinson's disease
    2021
    Summary Details
    OPEN
    Title: Plasma NfL, clinical subtypes and motor progression in Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.016
    Citation Count: 58
  • Summary Details
    OPEN
    Title: Consistent skin α-synuclein positivity in REM sleep behavior disorder – A two center two-to-four-year follow-up study
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.04.007
    Citation Count: 35
  • Summary Details
    OPEN
    Title: A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.07.013
    Citation Count: 27
  • Summary Details
    OPEN
    Title: Clinical perception and management of Parkinson's disease during the COVID-19 pandemic: A Canadian experience
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: other-oa
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.08.018
    Citation Count: 18
  • Summary Details
    OPEN
    Title: The commercial genetic testing landscape for Parkinson's disease
    Journal Name: Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc-nd
    DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.10.001
    Citation Count: 29
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.